The FDA has approved Jardiance 10mg and 25mg tablets to treat type 2 diabetes in children aged 10 years and above. Credit: i viewfinder / Shutterstock.com.

Eli Lilly and Boehringer Ingelheim have received approval from the US Food and Drug Administration (FDA) for Jardiance (empagliflozin) 10mg and 25mg tablets to treat type 2 diabetes in children aged 10 years and above.

The tablets are intended to reduce blood sugar, along with modification of diet and exercise in these patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Jardiance is a prescription medicine that helps lower the risk of hospitalisation and cardiovascular death for adults with heart failure.

It also helps decrease the risk of cardiovascular death in adults with type 2 diabetes.

Lilly diabetes and obesity global medical affairs senior vice-president Leonard Glass stated: “This decision brings us one step closer in our efforts to improve outcomes for this population and supports our larger commitment to advance treatment options for people living with a range of cardiometabolic conditions.”

The US regulator has approved the therapy based on data from the DINAMO Phase III study, which showed that Jardiance significantly reduced haemoglobin A1c, a blood test determining average blood sugar levels over the previous three months, compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The double-blind, parallel group, randomised and multicentre study recruited participants aged 10-17 years with type 2 diabetes previously treated with insulin or metformin.

Change from baseline in A1c at 26 weeks was the primary endpoint of the study.

Boehringer Ingelheim medicine and regulatory affairs senior vice-president Lennart Jungersten stated: “This FDA approval, which is based on the efficacy results and safety data from the DINAMO trial, marks an important milestone in helping address a clear unmet need for oral treatment options, in addition to metformin, to lower A1c in this rapidly rising population.”